Submission Information
What to know about submitting your research.

Abstracts are now live!

View + download the abstracts

Important Dates

Abstract Submission Site Opens

November 13, 2023 

Abstract Submission Deadline 

January 26, 2024 

Abstract Notifications Sent 

March 25, 2024 

Abstract Withdrawal Deadline 

April 1, 2024 

Late-Breaking Abstract Submission Site Opens 

February 19, 2024 

Late-Breaking Abstract Submission Site Deadline 

March 8, 2024 

Late-Breaking Abstract Notifications Sent 

April 1, 2024 

Abstracts Media Release Date April 8, 2024

Abstracts Available Online (Embargo Date) 

April 22, 2024 (4:30pm ET) 

Late-Breaking Abstracts Available Online (Embargo Date) 

May 3, 2024 (4:30pm ET) 


Late-Breaking Abstracts

Late-breaking abstracts submissions are solely for abstracts with late-breaking data and are not for abstracts submitted “late.” The Late-breaking abstracts deadline is not an extension of the general submission deadline. Late-breaking abstracts not chosen for the 14 open oral slots will not be accepted as posters or any other type of presentation or publication.

Applicants will be asked to answer the question: “What makes your abstract news-worthy, ground-breaking, or high-impact?”

General Requirements

  • All abstracts must be submitted in clear and concise English. Spelling may be in U.S. English or UK English.
  • In most cases, Greek letters and other special characters will transfer from your word processing software via copy and paste functions.
  • Remove all track changes before submitting your abstract; these changes can be picked up with copy and paste functions, making the abstract incoherent.
  • The title should be entered exactly as it is to appear online—titles should be submitted in title case.
  • The names of all co-authors and their institutional affiliations must be provided at time of submission.
    • Any names excluded in submission will not be listed in the author block of the publication online or in the Journal.
  • It is the responsibility of the submitter to proofread the abstract and author list carefully.
  • Tables and figures may be uploaded via a photo file type.
  • The abstract may be structured (ie. divided into sections: introduction, methods, results, conclusions) or unstructured.
  • Do not use bold type or underline formatting—italic type is acceptable.
  • Changes to abstracts may be made by the submitter prior to the close of the submission deadline.
    • Changes after the submission deadline but before the review has started must be sent to—all changes should include the tracking number and title of the abstract and explicitly say what changes need to be made. New authors must be listed in order and with their institutions, locations, and email addresses.
    • No changes will be made to any abstract or author block after Review has started on Feb. 1, 2024. 

The presenting author of abstracts selected for oral or poster presentation must attend the Annual Meeting in person. If the original designated presenting author cannot attend, a co-author may be designated as an alternative presenter.

View Presentation Information

*New in 2024* Plain Language

The ASGCT Patient Outreach Committee is looking to make research findings more accessible to the rare disease community by adding the additional optional submission of a plain language summary of your research. Submissions of the plain language summary will not be used in review for abstract acceptance. These summaries will instead be reviewed by the Patient Outreach Committee and the top 10 summaries will have a special highlight on our social media and in our patient outreach materials. All plain language summaries will be under the same embargo policy as the abstracts.

Suggestions for your summary: 

  • When writing this summary, imagine you are excited to share this information with a family member, friend or neighbor who does not have your scientific expertise. 
  • Skip the details and jump straight to how the methods or findings may impact the disease community or the field.  
  • Start with the most important message you would want to share with a patient (or individual with potential to receive cell gene therapy treatment), caregiver, or advocate and add any further need-to-know details from there.  
  • Be wary of including details and scientific jargon that may cloud the main message.

For tips on plain language, please visit

Review and Selection

All abstracts are reviewed by a group of volunteer reviewers assigned to each category. Abstract reviewers consider a number of variables in rating the abstract for selection of oral presentations. General considerations include quality of the research and presentation, the strength of the results and methods, and whether the reported research significantly advances the field. Additionally, each review committee is able to put forward suggested abstracts for the Presidential Symposium and the Clinical Trials Symposium. These abstracts are then further reviewed by the President, President-elect, Secretary, and a group of reviewers of their choosing. 

The committees also reject any submissions that are clear advertisements of a product or service, or show very little scientific merit.

Tips for Submitting the Best Abstract

  • Clarity is vital.
  • Choose your category wisely.
  • Highlight new and novel aspects and be clear about what advancements you have made.
  • Clearly describe the model system(s) used.
  • Avoid too many background details—get to the point.
  • Edit and proofread your abstract—if needed, use English editing support.

2024 Notification

  • Abstract acceptance notifications will be sent via email on March 25, 2024 after all reviewing has been completed. If you don’t receive your notification email by April 30, 2024, please contact Program Manager Kim Durham

  • Accepted abstracts will be scheduled as either an oral presentation or a poster presentation. 

  • The official acceptance letter, which includes the presentation date, time, and location, will be posted on the abstract submission site. 

  • International abstract submitters who plan to attend the 27th Annual Meeting will need to apply for a visa to travel to the meeting in Baltimore, Maryland, USA.

  • Please note: The amount of time required to obtain a visa has increased tremendously. Abstract submitters can generate invitation letters here to apply for visas immediately after submitting an abstract. Please contact with any questions.

Contact Information

General questions on abstract submission policies or notifications should be emailed to

ASGCT Annual Meeting registration, housing, membership, and login reset requests should be sent to

View Presentation Information

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.